Organic compounds from the Ginkgo biloba plant improve cognitive function post-stroke

De GruyterMar 14 2024

Ginkgo Diterpene Lactone Meglumine (GDLM), a group of organic compounds that derive from the Ginkgo biloba plant, can improve cognitive function in patients who recently experienced an acute ischemic stroke, according to new research published in De Gruyter's Open Medicine. The study is the first to examine the potential of GDLM for improving cognitive function in acute ischemic stroke patients.

During a stroke, impaired blood flow to the brain results in oxygen deprivation and an inflammatory response which ultimately leads to neuronal cell death. Consequently, cognitive impairment is common in stroke patients, and can significantly affect quality of life and independence. While drugs are available to slow the progression of such impairment, they can lack efficacy and present safety issues. Safe treatments for cognitive impairment in the early years after a stroke are urgently needed.

GDLM could have potential as such a treatment. Ginkgo biloba, from which it derives, has been used in traditional Chinese medicine to treat cardiovascular disease, and GDLM itself has been shown to inhibit platelet aggregation and thus reduce blood clotting.

Professor Xianghong Liu of Xi'an High Tech Hospital, China and colleagues recruited 126 stroke patients for their study. Half the patients were treated with 25 mg of GDLM per day for 14 days, as well as receiving standard care, while the other half acted as a control group and received standard care alone. Over the next three to six months, the researchers performed a variety of tests on the patients, including measurements of inflammation and coagulation markers, and assessments of cognitive function.

Levels of inflammatory markers fell in both the GDLM group and control group over the first 14 days, but the reduction in inflammation was greater in the GDLM group. Levels of coagulation markers had also dropped significantly in the GDLM group by day 14, but not in the control group, suggesting that GDLM treatment has an anti-coagulant effect. As blood clots often contribute to the blood vessel blockages that cause stroke, anti-coagulant effects are useful in the aftermath of a stroke.

Both the GDLM and control group demonstrated a reduction in cognitive function after the stroke; however, between three and six months afterwards it began to improve again, with the GDLM group making greater progress than the control group.

Overall, GDLM treatment was well tolerated by the patients. This, together with the evidence of anti-inflammatory, anti-coagulant and cognitive efficacy presented by the study, suggests that further research is warranted to determine whether this plant-derived therapy could become a treatment for acute ischemic stroke.

Ginkgo Diterpene Lactone Meglumine (GDLM), a group of organic compounds that derive from the Ginkgo biloba plant, can improve cognitive function in patients who recently experienced an acute ischemic stroke, according to new research published in De Gruyter's Open Medicine. The study is the first to examine the potential of GDLM for improving cognitive function in acute ischemic stroke patients.

During a stroke, impaired blood flow to the brain results in oxygen deprivation and an inflammatory response which ultimately leads to neuronal cell death. Consequently, cognitive impairment is common in stroke patients, and can significantly affect quality of life and independence. While drugs are available to slow the progression of such impairment, they can lack efficacy and present safety issues. Safe treatments for cognitive impairment in the early years after a stroke are urgently needed.

GDLM could have potential as such a treatment. Ginkgo biloba, from which it derives, has been used in traditional Chinese medicine to treat cardiovascular disease, and GDLM itself has been shown to inhibit platelet aggregation and thus reduce blood clotting.

Professor Xianghong Liu of Xi'an High Tech Hospital, China and colleagues recruited 126 stroke patients for their study. Half the patients were treated with 25 mg of GDLM per day for 14 days, as well as receiving standard care, while the other half acted as a control group and received standard care alone. Over the next three to six months, the researchers performed a variety of tests on the patients, including measurements of inflammation and coagulation markers, and assessments of cognitive function.

Levels of inflammatory markers fell in both the GDLM group and control group over the first 14 days, but the reduction in inflammation was greater in the GDLM group. Levels of coagulation markers had also dropped significantly in the GDLM group by day 14, but not in the control group, suggesting that GDLM treatment has an anti-coagulant effect. As blood clots often contribute to the blood vessel blockages that cause stroke, anti-coagulant effects are useful in the aftermath of a stroke.

Both the GDLM and control group demonstrated a reduction in cognitive function after the stroke; however, between three and six months afterwards it began to improve again, with the GDLM group making greater progress than the control group.

Overall, GDLM treatment was well tolerated by the patients. This, together with the evidence of anti-inflammatory, anti-coagulant and cognitive efficacy presented by the study, suggests that further research is warranted to determine whether this plant-derived therapy could become a treatment for acute ischemic stroke.